Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTO NASDAQ:AVRO NASDAQ:MGTX NASDAQ:PRVL NASDAQ:REPL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsAVROAVROBIO$9.98$0.88▼$1.65$62.85M1.23269,831 shs206,800 shsMGTXMeiraGTx$8.14+2.6%$7.86$4.55▼$8.98$637.95M1.34397,952 shs264,296 shsPRVLPrevail Therapeutics$23.00$23.01$9.02▼$23.35$787.66M1.59955,800 shsN/AREPLReplimune Group$4.74+9.0%$5.06$2.68▼$17.00$339.54M0.425.01 million shs3.70 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%-84.98%AVROAVROBIO0.00%0.00%0.00%0.00%0.00%MGTXMeiraGTx+1.28%-6.60%+4.20%-8.54%+70.91%PRVLPrevail Therapeutics0.00%0.00%0.00%0.00%0.00%REPLReplimune Group-4.61%-6.45%-24.08%-65.56%-59.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsAVROAVROBIO$9.98$0.88▼$1.65$62.85M1.23269,831 shs206,800 shsMGTXMeiraGTx$8.14+2.6%$7.86$4.55▼$8.98$637.95M1.34397,952 shs264,296 shsPRVLPrevail Therapeutics$23.00$23.01$9.02▼$23.35$787.66M1.59955,800 shsN/AREPLReplimune Group$4.74+9.0%$5.06$2.68▼$17.00$339.54M0.425.01 million shs3.70 million shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%0.00%-84.98%AVROAVROBIO0.00%0.00%0.00%0.00%0.00%MGTXMeiraGTx+1.28%-6.60%+4.20%-8.54%+70.91%PRVLPrevail Therapeutics0.00%0.00%0.00%0.00%0.00%REPLReplimune Group-4.61%-6.45%-24.08%-65.56%-59.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences 3.50Strong Buy$6.00∞ UpsideAVROAVROBIO 0.00N/AN/AN/AMGTXMeiraGTx 2.33Hold$24.00194.84% UpsidePRVLPrevail Therapeutics 0.00N/AN/AN/AREPLReplimune Group 1.91Reduce$6.5037.13% UpsideCurrent Analyst Ratings BreakdownLatest APTO, PRVL, REPL, MGTX, and AVRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025REPLReplimune GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MGTXMeiraGTxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MGTXMeiraGTxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025REPLReplimune GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/19/2025REPLReplimune GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight9/8/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral8/15/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.007/30/2025REPLReplimune GroupCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Overweight7/23/2025REPLReplimune GroupBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$17.00 ➝ $3.007/23/2025REPLReplimune GroupBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Underperform$27.00 ➝ $2.007/23/2025REPLReplimune GroupHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AAVROAVROBION/AN/AN/AN/A$2.13 per shareN/AMGTXMeiraGTx$33.28M19.68N/AN/A$0.87 per share9.36PRVLPrevail TherapeuticsN/AN/AN/AN/A$4.85 per shareN/AREPLReplimune GroupN/AN/AN/AN/A$5.40 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/AAVROAVROBIO$12.16M$0.692.03N/AN/AN/A-50.52%-47.13%N/AMGTXMeiraGTx-$147.79M-$2.04N/A21.42N/A-415.39%-314.44%-63.28%11/12/2025 (Estimated)PRVLPrevail Therapeutics-$63.19M-$2.22N/AN/AN/AN/A-55.57%-48.14%N/AREPLReplimune Group-$247.30M-$3.24N/AN/AN/AN/A-69.34%-52.81%11/11/2025 (Estimated)Latest APTO, PRVL, REPL, MGTX, and AVRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025MGTXMeiraGTx-$0.51N/AN/AN/A$7.71 millionN/A11/11/2025Q2 2026REPLReplimune Group-$0.86N/AN/AN/A$0.50 millionN/A8/14/2025Q2 2025MGTXMeiraGTx-$0.52-$0.48+$0.04-$0.48$8.00 million$3.69 million8/7/2025Q1 2026REPLReplimune Group-$0.83-$0.95-$0.12-$0.95$0.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APRVLPrevail TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A1.051.05AVROAVROBION/A26.1726.17MGTXMeiraGTx26.290.880.88PRVLPrevail TherapeuticsN/A7.567.56REPLReplimune Group0.216.946.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%AVROAVROBIO62.63%MGTXMeiraGTx67.48%PRVLPrevail Therapeutics86.80%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences1.33%AVROAVROBIO9.20%MGTXMeiraGTx7.50%PRVLPrevail Therapeutics57.20%REPLReplimune Group5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataAVROAVROBIO1344.89 million40.76 millionOptionableMGTXMeiraGTx30080.45 million74.41 millionOptionablePRVLPrevail Therapeutics6634.25 millionN/ANot OptionableREPLReplimune Group21078.06 million74.00 millionOptionableAPTO, PRVL, REPL, MGTX, and AVRO HeadlinesRecent News About These CompaniesReplimune Group (NASDAQ:REPL) Given Sell (D-) Rating at Weiss RatingsOctober 14 at 3:00 PM | marketbeat.comREPLIMUNE ALERT: Bragar Eagel & Squire, P.C. is Investigating Replimune Group, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 8, 2025 | globenewswire.comReplimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Hold" from AnalystsOctober 3, 2025 | marketbeat.comReplimune Group (REPL) Receives a Hold from BarclaysSeptember 25, 2025 | theglobeandmail.comREPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer DrugSeptember 24, 2025 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPLSeptember 23, 2025 | prnewswire.comInvestors in Replimune Group, Inc. Should Contact Levi & Korsinsky Before September 22, 2025 to Discuss Your Rights – REPLSeptember 22, 2025 | globenewswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneSeptember 22, 2025 | businesswire.comREPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit Filed by The Rosen Law FirmSeptember 22, 2025 | prnewswire.comReplimune Group, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before September 22, 2025 to Discuss Your Rights - REPLSeptember 22, 2025 | prnewswire.comReplimune Group, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REPLSeptember 22, 2025 | prnewswire.comREPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 22, 2025 | prnewswire.comReplimune Group (REPL) Gets a Hold from BarclaysSeptember 21, 2025 | theglobeandmail.comREPL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Replimune Group, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitSeptember 21, 2025 | globenewswire.comREPL FINAL DEADLINE ALERT: Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens BermanSeptember 21, 2025 | globenewswire.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ReplimuneSeptember 21, 2025 | globenewswire.comREPL DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPLSeptember 21, 2025 | globenewswire.comREPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities ...September 21, 2025 | tmcnet.comReplimune Group (REPL): Valuation in Focus After FDA Setback and Investor Lawsuit AnnouncementsSeptember 21, 2025 | finance.yahoo.comREPL Deadline: Rosen Law Firm Encourages Replimune Group, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important September 22 Deadline in Securities Class Action First Filed by the Firm – REPLSeptember 20, 2025 | businesswire.comReplimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens BermanSeptember 20, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Replace Your Fixed Income With This Dividend ETFBy Jordan Chussler | September 24, 2025APTO, PRVL, REPL, MGTX, and AVRO Company DescriptionsAptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.AVROBIO NASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.MeiraGTx NASDAQ:MGTX$8.14 +0.21 (+2.65%) Closing price 04:00 PM EasternExtended Trading$8.16 +0.02 (+0.31%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Prevail Therapeutics NASDAQ:PRVLPrevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Replimune Group NASDAQ:REPL$4.74 +0.39 (+8.97%) Closing price 04:00 PM EasternExtended Trading$4.70 -0.04 (-0.74%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
